124 related articles for article (PubMed ID: 38890412)
1. A platform technology for ultra-long acting intratumoral therapy.
Henise J; Hangasky JA; Charych D; Carreras CW; Ashley GW; Santi DV
Sci Rep; 2024 Jun; 14(1):14000. PubMed ID: 38890412
[TBL] [Abstract][Full Text] [Related]
2. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Injection Administration of Irinotecan-Loaded Microspheres: In Vitro and In Vivo Evaluation.
Zhu S; Dou M; Huang G
AAPS PharmSciTech; 2018 Nov; 19(8):3829-3838. PubMed ID: 30280351
[TBL] [Abstract][Full Text] [Related]
4. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
Fontaine SD; Hann B; Reid R; Ashley GW; Santi DV
Cancer Chemother Pharmacol; 2019 Oct; 84(4):729-738. PubMed ID: 31321449
[TBL] [Abstract][Full Text] [Related]
5. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Hoch U; Staschen CM; Johnson RK; Eldon MA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues.
Ingram N; McVeigh LE; Abou-Saleh RH; Maynard J; Peyman SA; McLaughlan JR; Fairclough M; Marston G; Valleley EMA; Jimenez-Macias JL; Charalambous A; Townley W; Haddrick M; Wierzbicki A; Wright A; Volpato M; Simpson PB; Treanor DE; Thomson NH; Loadman PM; Bushby RJ; Johnson BRG; Jones PF; Evans JA; Freear S; Markham AF; Evans SD; Coletta PL
Theranostics; 2020; 10(24):10973-10992. PubMed ID: 33042265
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
[No Abstract] [Full Text] [Related]
9. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
[TBL] [Abstract][Full Text] [Related]
10. PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors.
Thomas A; Fontaine SD; Diolaiti ME; Desai P; Kumar R; Takahashi N; Sciuto L; Nichols S; Ashworth A; Feng FY; Ashley GW; Nguyen M; Pommier Y; Santi DV
Mol Cancer Ther; 2022 Nov; 21(11):1722-1728. PubMed ID: 35999657
[TBL] [Abstract][Full Text] [Related]
11. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
12. A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
[TBL] [Abstract][Full Text] [Related]
13. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
14. Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system.
McDannold N; Zhang Y; Supko JG; Power C; Sun T; Vykhodtseva N; Golby AJ; Reardon DA
Sci Rep; 2020 May; 10(1):8766. PubMed ID: 32472017
[TBL] [Abstract][Full Text] [Related]
15. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
16. PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice.
Jung J; Schneider EL; Zhang W; Song H; Zhang M; Chou W; Meher N; VanBrocklin HF; Barcellos-Hoff MH; Ozawa T; Gilbert MR; Santi DV
Sci Rep; 2024 Jun; 14(1):14175. PubMed ID: 38898077
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot.
Kim DY; Kwon DY; Kwon JS; Park JH; Park SH; Oh HJ; Kim JH; Min BH; Park K; Kim MS
Biomaterials; 2016 Apr; 85():232-45. PubMed ID: 26874285
[TBL] [Abstract][Full Text] [Related]
18. Injectable bio-multifunctional hyaluronic acid-based hydrogels loaded with poly ADP-ribose polymerase inhibitors for ovarian cancer therapy.
Han X; Li G; You S; Shen M; Xu Y; Yang H; Lu C; Zhang M; Fang J; Zhou Q; Yao Q
Int J Biol Macromol; 2024 Jun; 270(Pt 1):132275. PubMed ID: 38734345
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
20. A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models.
Fontaine SD; Ashley GW; Houghton PJ; Kurmasheva RT; Diolaiti M; Ashworth A; Peer CJ; Nguyen R; Figg WD; Beckford-Vera DR; Santi DV
Cancer Res; 2021 Feb; 81(4):1076-1086. PubMed ID: 33323380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
